Latest

12.03.2024

Coherus sells its last biosimilar Udenyca to Intas for up to $558M as company homes in on novel cancer meds

Read Article
06.27.2024

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Read Article
03.11.2024

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Read Article
02.28.2024

CalciMedica Announces Presentation of a Preclinical Study of Auxora in Acute Kidney Injury at the AKI & CRRT Conference

Read Article
02.13.2024

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for Treatment of Severe Acute Kidney Injury

Read Article
01.22.2024

CalciMedica Announces Private Placement of up to Approximately $55 Million

Read Article
06.05.2023

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Car

Read Article
05.18.2023

OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

Read Article
Up NextAbout Us